Iprixon Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑mediated constriction. This anticholinergic action reduces bronchoconstriction, allowing the airways to stay open and facilitating easier airflow.

The specific dose and frequency of Iprixon Neb are determined by the prescribing clinician based on the patient’s severity of disease, age, and response to therapy. Healthcare professionals tailor the nebulized volume and administration schedule to each individual case.

Safety data for Iprixon Neb in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Iprixon Neb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iprixon Neb combines an anticholinergic (ipratropium) with a short‑acting β2‑agonist (salbutamol), offering additive bronchodilation. This dual mechanism can provide faster and more sustained relief compared with either agent alone, especially in patients who need both muscarinic blockade and β2‑adrenergic stimulation.

Store Iprixon Neb at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture, direct sunlight and extreme temperatures to maintain stability and potency.

Iprixon Neb is a nebulizer solution intended for inhalation. The prescribed volume is placed in a compatible nebulizer device, and the patient inhales the aerosolized medication until the dose is fully delivered, following the clinician’s instructions.

Serious risks include paradoxical bronchospasm, angioedema, severe tachycardia or arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should be monitored for these events, and treatment should be stopped immediately if they occur.

Iprixon Neb should be avoided in individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation. Caution is also advised for patients with narrow‑angle glaucoma, severe cardiac disease, or uncontrolled hypertension, and it is contraindicated in those with a documented allergy to the product.